The Arrhythmogenic Calmodulin p.Phe142Leu Mutation Impairs C-domain Ca\textsuperscript{2+} Binding but Not Calmodulin-dependent Inhibition of the Cardiac Ryanodine Receptor\*<sup>1</sup>

Received for publication, November 4, 2016, and in revised form, November 30, 2016 Published, JBC Papers in Press, December 7, 2016, DOI 10.1074/jbc.M116.766253

Mads Toft Søndergaard, Filip Van Petegem, Michael Toft Overgaard, S. R. Wayne Chen

From the \*Department of Chemistry and Bioscience, Aalborg University, 9220 Aalborg, Denmark, the \*Libin Cardiovascular Institute of Alberta, the Department of Physiology and Pharmacology and the Department of Biochemistry and Molecular Biology, University of Calgary, Calgary, Alberta T2N 1N4, Canada, the \*Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada, and the \*Department of Molecular Biophysics and Physiology, Rush University Medical Center, Chicago, Illinois 60612

Edited by Roger J. Colbran

A number of point mutations in the intracellular Ca\textsuperscript{2+}-sensing protein calmodulin (CaM) are arrhythmogenic, yet their underlying mechanisms are not clear. These mutations generally decrease Ca\textsuperscript{2+} binding to CaM and impair inhibition of CaM-regulated Ca\textsuperscript{2+} channels like the cardiac Ca\textsuperscript{2+} release channel (ryanodine receptor, RyR2), and it appears that attenuated CaM Ca\textsuperscript{2+} binding correlates with impaired CaM-dependent RyR2 inhibition. Here, we investigated the RyR2 inhibitory action of the CaM p.Phe142Leu mutation (F142L; numbered including the start-Met), which markedly reduces CaM Ca\textsuperscript{2+} binding. Surprisingly, CaM-F142L had little to no aberrant effect on RyR2-mediated store overload-induced Ca\textsuperscript{2+} release in HEK293 cells compared with CaM-WT. Furthermore, CaM-F142L enhanced CaM-dependent RyR2 inhibition at the single channel level compared with CaM-WT. This is in stark contrast to the actions of arrhythmogenic CaM mutations N54I, D96V, N98S, and D130G, which all diminish CaM-dependent RyR2 inhibition. Thermodynamic analysis showed that apoCaM-F142L converts an endothermal interaction between CaM and the CaM-binding domain (CaMBD) of RyR2 into an exothermal one. Moreover, NMR spectra revealed that the CaM-F142L-CaMBD interaction is structurally different from that of CaM-WT at low Ca\textsuperscript{2+}. These data indicate a distinct interaction between CaM-F142L and the RyR2 CaMBD, which may explain the stronger CaM-dependent RyR2 inhibition by CaM-F142L, despite its reduced Ca\textsuperscript{2+} binding. Collectively, these results add to our understanding of CaM-dependent regulation of RyR2 as well as the mechanistic effects of arrhythmogenic CaM mutations. The unique properties of the CaM-F142L mutation may provide novel clues on how to suppress excessive RyR2 Ca\textsuperscript{2+} release by manipulating the CaM-RyR2 interaction.

Point mutations in one of the three extremely conserved calmodulin (CaM)\textsuperscript{2}−encoding genes, CALM1–3, result in life-threatening ventricular arrhythmias likely due to altered CaM-regulation of the ion channels that govern cardiac excitation-contraction (1–8). The CaM-N54I and -N98S mutations (numbering includes start-Met) were identified in individuals with catecholaminergic polymorphic ventricular tachycardia (CPVT). The CaM-D96V, -D130G, and -F142L mutations were found in individuals with long QT syndrome (LQTS) (1, 2). Interestingly, the CaM-N98S mutant also apparently causes LQTS or a mixed phenotype, depending on the genetic background (4). Not only do these various mutations impose different cardiac arrhythmias, but it appears that their disease mechanisms differ at the molecular level for each CaM target, even within the same arrhythmia type (6–11). One such CaM target is the cardiac Ca\textsuperscript{2+} release channel/ryanodine receptor (RyR2). RyR2 mediates Ca\textsuperscript{2+} release from the sarcoplasmic reticulum (SR) in cardiomyocytes (12, 13). The RyR2 protein forms homotetrameric channels in the SR membrane with a large cytosolic domain that interacts with numerous proteins and ligands, which regulate RyR2 Ca\textsuperscript{2+} release (12, 13). During cardiac excitation-contraction coupling, RyR2 channels are activated by

\* This work was supported by research grants from the Danish Council for Independent Research (DFF-4181-00447), the Olbelske Family Foundation, the Novo Nordic Foundation (NNF15OC001776299), and the Lundbeck Foundation (2013-14432) (to M. T. O.) and by a postdoctoral fellowship from the Danish Council for Independent Research (DFF-4093-00242 to M. T. S.). This work was also supported by research grants from the Canadian Institutes of Health Research, the Heart and Stroke Foundation of Canada, the Canada Foundation for Innovation, and the Heart and Stroke Foundation/Libin Professorship in Cardiovascular Research (to S. R. W. C.). Support for this research was also provided by National Institutes of Health Grants AR054098 and HL057832 (to M. F.) and HL057832 (to S. R. W. C.). The authors declare that they have no conflicts of interest with the contents of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

\* Author’s Choice—Final version free via Creative Commons CC-BY license.

1 To whom correspondence should be addressed: Dept. of Chemistry and Bioscience, Aalborg University, Fredrik Bajers Vej 7H, 9220 Aalborg, Denmark. E-mail: mto@bio.aau.dk.

2 The abbreviations used are: CaM, calmodulin; CPVT, catecholaminergic polymorphic ventricular tachycardia; LQTS, long QT syndrome; RyR2, cardiac ryanodine receptor; SR, sarcoplasmic reticulum; CaMBD, CaM-binding domain; SOICR, store overload-induced Ca\textsuperscript{2+} release; GoF, gain of function; LoF, loss of function; ER, endoplasmic reticulum; Ctrl, control; MOT, mean open time; MCT, mean closed time; ITC, isothermal titration calorimetry; ANOVA, analysis of variance; TCEP, tris(2-carboxyethyl)phosphine; Fl, fluorescence intensity; PO, open probability.
CaM-F142L Impairs Ca\textsuperscript{2+} Binding but Not RyR2 Inhibition

Ca\textsuperscript{2+} entry into the cytosol through sarcolemmal voltage-gated Ca\textsuperscript{2+} channels (Ca\textsubscript{v}1.2). This Ca\textsuperscript{2+} entry triggers RyR2-mediated SR Ca\textsuperscript{2+} release via a process called Ca\textsuperscript{2+}-induced Ca\textsuperscript{2+} release, which results in the rise in cytosolic free Ca\textsuperscript{2+} ([Ca\textsuperscript{2+}]\textsubscript{cyt}) and thereby drives contraction (14). RyR2 channels are sensitive to both [Ca\textsuperscript{2+}]\textsubscript{cyt} and the SR luminal free Ca\textsuperscript{2+} ([Ca\textsuperscript{2+}]\textsubscript{sp}) as well as a plethora of regulatory signals (13). One of these regulatory signals is CaM binding to RyR2, which generally inhibits Ca\textsuperscript{2+} release both at the diastolic and systolic [Ca\textsuperscript{2+}]\textsubscript{cyt}.

CaM is a ubiquitously expressed sensor of cytosolic Ca\textsuperscript{2+} signals that has two Ca\textsuperscript{2+}-coordinating regions (Ca\textsuperscript{2+}-binding domains, or CaMBD) each containing two EF-hand motifs. These two domains are separated by a flexible linker, and thus one CaM protein binds up to four Ca\textsuperscript{2+} (Fig. 1). The two domains of CaM display distinct affinities and kinetics for binding to Ca\textsuperscript{2+}. This allows the CaM domains to have both independent and correlated interactions with different CaM targets (3, 15–17). Moreover, the Ca\textsuperscript{2+} binding attributes of either domain are affected by Ca\textsuperscript{2+} binding to the other domain as well as by the binding of CaM to protein targets (8, 17–20). In addition, protein complexes regulated by CaM generally contain more than one region for their interaction with the two CaM domains (3, 21, 22). For example, the binding of the CaM C-domain to the RyR2 CaM-binding domain (CaMBD) (Arg-3581–Pro-3607, human RyR2) is a prerequisite for CaM-dependent RyR2 inhibition. The RyR2 CaMBD also interacts with the CaM N-domain (Fig. 1), although less is known about this interaction (3, 8, 23–26). The pivotal role of this CaMBD in CaM-dependent RyR2 inhibition has been demonstrated unequivocally, but some studies suggest that other putative CaMBD in RyR2 may be involved as well (8, 26–29).

Recently, we showed that both the CPVT-causing CaM-N54I and the CPVT- and LQTS-causing CaM-N98S, as well as the LQTS-causing CaM-D96V and -D130G mutations markedly reduce inhibition of RyR2 Ca\textsuperscript{2+} release during store-overload-induced Ca\textsuperscript{2+} release (SOICR) (8). The CaM-D96V, -N98S, and -D130G mutations directly affect Ca\textsuperscript{2+}-coordinating residues in the C-domain. Thus, the diminished ability of these mutations to regulate RyR2 function is potentially explained by the reduced C-domain Ca\textsuperscript{2+} binding. Unlike the CaM-D96V, -N98S, and -D130G mutations, CaM-F142L does not affect a Ca\textsuperscript{2+}-coordinating residue but still reduces CaM C-domain Ca\textsuperscript{2+} binding (2). In the X-ray structure of CaM complexed with the RyR1 CaMBD, the Phe-142 residue directly contributes to the CaM-CaMBD binding interface in contrast to the CaM Asn-54, Asn-98, Asp-96, and Asp-130 residues. We used a combination of functional, biophysical, and structural assays to investigate in detail the action of the LQTS-causing CaM-F142L mutation on RyR2 regulation. Unexpectedly, we found that the F142L mutation caused only a minor reduction in RyR2 inhibition by CaM (compared with CaM-WT), despite the markedly reduced CaM-F142L C-domain Ca\textsuperscript{2+} binding. Even more surprisingly, the F142L mutation enhanced the inhibitory action of CaM in RyR2 single channel experiments (i.e. displayed a CaM gain-of-function (GoF) effect). These actions are unique to the CaM-F142L mutation as compared with the CaM-N54I, -D96V, -N98S, and -D130G mutations.

![FIGURE 1. Overview of CaM and selected CaM mutations. A, the primary structure of CaM (N-domain, Met-1–Thr-80; C-domain, Asp-81–Lys-149) with EF-hands 1–4 aligned. Dashed boxes indicate α-helices and connected black boxes the Ca\textsuperscript{2+} coordinating residues. Red bars highlight individual sites for arrhythmogenic mutations (N54I, D96V, N98S, D130G, and F142L). B, representative tertiary structure of CaM. Ca\textsuperscript{2+}-saturated CaM binding to a 27-residue peptide corresponding to part of the CaMBD in RyR1 (Lys-3614–Pro-3640) (Protein Data Bank code 2BCX) is shown. Protein and peptide secondary structures are represented schematically. The N-domain of CaM is indicated in blue, the C-domain in orange, and the peptide in gray. Sites of arrhythmogenic CaM mutations are highlighted as green stick representations (non-mutated residues) and Ca\textsuperscript{2+} ions as black spheres. RyR1 CaMBD residues (Trp-3620, Leu-3624, and Phe-3636) corresponding to RyR2 CaMBD residues Trp-3587, Leu-3591, and Phe-3603 are highlighted as magenta stick representations.](image-url)
CaM-F142L Impairs Ca\(^{2+}\) Binding but Not RyR2 Inhibition

The CaM-F142L Mutation Enhances Inhibition of Single RyR2 Channels—Next, we tested the action of the CaM mutations on single RyR2 channels incorporated into lipid bilayers. Luminal \([Ca^{2+}]_{\text{free}}\) was kept at 1 mM, and the cytosolic \([Ca^{2+}]_{\text{free}}\) was set at 10 mM. The cytosolic solution also contained 1 mM \([Mg^{2+}]_{\text{free}}\) and 5 mM ATP to approximate the levels present in cells. The 10 mM cytosolic \([Ca^{2+}]_{\text{free}}\) approximates the level that RyR2 encounters during systole (see “Experimental Procedures”). Single RyR2 channel function was measured before and after the addition of 1 mM CaM-WT, -F142L, -N54I, -N98S, -D96V, -N98S, or -D130G to the cytosolic solution (Fig. 3). Control (Ctrl) recordings in the absence of CaM were also included. The addition of CaM-WT significantly lowered the RyR2 open probability \((P_O)\) from 0.47 to 0.35 compared with control, consistent with CaM-WT inhibition of RyR2-mediated Ca\(^{2+}\) release (Fig. 3D). CaM-WT reduced the mean open time (MOT) and increased the mean closed time (MCT), although these changes individually were not statistically significant \((p = 0.18\) and 0.05 against Ctrl) (Fig. 3, E and F). In contrast, the C-domain mutations, CaM-D96V, -N98S, and -D130G, in contrast to CaM-WT, do not appear to inhibit RyR2 function (but this is due to almost equal decreases in both MOT and MCT compared with no CaM present). In contrast, the CaM N-domain N54I mutation did not significantly affect RyR2 function \((P_O, \text{MCT or MOT})\) under these experimental conditions, suggesting that aberrant RyR2 regulation by CaM-N54I is mechanistically distinct from that caused by the CaM C-domain mutations \((8, 17)\).

Strikingly, the C-domain CaM-F142L mutation had an opposite action on single RyR2 channel function. CaM-F142L significantly lowered the RyR2 \(P_O\) even more so than CaM-WT \((P_O = 0.18\) versus 0.35) (Fig. 3D). The CaM-F142L mutation caused a significant MOT decrease compared with both CaM-WT and the control. The CaM-N98S mutation significantly decreased MOT compared with the control. These results suggest that: 1) these CaM mutations do interact with RyR2 as also shown in previous studies \((7, 8, 10)\); and 2) CaM mutations D96V, N98S, and D130G, in contrast to CaM-WT, do not appear to inhibit RyR2 function (but this is due to almost equal decreases in both MOT and MCT compared with no CaM present).

The CaM-F142L Mutation Reduces Ca\(^{2+}\) Release in the Presence of the RyR2 CaMBD Peptide—The ability of CaM to inhibit RyR2 Ca\(^{2+}\) release depends both on Ca\(^{2+}\) binding to the unit for ER Ca\(^{2+}\) load and not the relative effects of the CaM variants. On the other hand, expression of CaM-WT increased the termination threshold by 4% (WT 64% versus control 60%, \(p < 0.01\)) and minutely reduced the fractional ER Ca\(^{2+}\) release (WT 30% versus control 32%, \(p = 0.1\)), although the latter was not statistically significant (Fig. 2, A and E). Neither CaM-WT nor CaM-F142L expression affected the activation threshold (Fig. 2, A–C). The control and CaM-WT results here are highly consistent with those reported previously (27). Taken together, CaM-F142L slightly reduced the SOICR termination threshold or, in other words, had a slightly less inhibitory action on RyR2-mediated Ca\(^{2+}\) release compared with CaM-WT. For comparison, we previously reported equivalent experiments showing that CPVT-causing (N54I), CPVT- and LQTS-causing (N98S), and LQTS-causing CaM mutations (D96V and D130G) all dramatically alter the Ca\(^{2+}\) release termination threshold (8). Specifically, the CaM-N54I, -D96V, -N98S, and -D130G mutations reduced the termination threshold by 12, 17, 18, and 16%, respectively. These variants also minimally, but significantly, reduced the activation threshold (−5%) (8). Thus, the action of the CaM-F142L mutant on RyR2 function appeared very different from that of CaM-N54I, -D96V, -N98S, and -D130G.

The CaM-F142L Mutation Enhances Inhibition of Single RyR2 Channels—Next, we tested the action of the CaM mutations on single RyR2 channels incorporated into lipid bilayers. Luminal \([Ca^{2+}]_{\text{free}}\) was kept at 1 mM, and the cytosolic \([Ca^{2+}]_{\text{free}}\) was set at 10 mM. The cytosolic solution also contained 1 mM \([Mg^{2+}]_{\text{free}}\) and 5 mM ATP to approximate the levels present in cells. The 10 mM cytosolic \([Ca^{2+}]_{\text{free}}\) approximates the level that RyR2 encounters during systole (see “Experimental Procedures”). Single RyR2 channel function was measured before and after the addition of 1 mM CaM-WT, -F142L, -N54I, -D96V, -N98S, or -D130G to the cytosolic solution (Fig. 3). Control (Ctrl) recordings in the absence of CaM were also included. The addition of CaM-WT significantly lowered the RyR2 open probability \((P_O)\) from 0.47 to 0.35 compared with control, consistent with CaM-WT inhibition of RyR2-mediated Ca\(^{2+}\) release (Fig. 3D). CaM-WT reduced the mean open time (MOT) and increased the mean closed time (MCT), although these changes individually were not statistically significant \((p = 0.18\) and 0.05 against Ctrl) (Fig. 3, E and F). In contrast, the C-domain mutations, CaM-D96V, -N98S, and -D130G, in contrast to CaM-WT, do not appear to inhibit RyR2 function (but this is due to almost equal decreases in both MOT and MCT compared with no CaM present). In contrast, the CaM N-domain N54I mutation did not significantly affect RyR2 function \((P_O, \text{MCT or MOT})\) under these experimental conditions, suggesting that aberrant RyR2 regulation by CaM-N54I is mechanistically distinct from that caused by the CaM C-domain mutations \((8, 17)\).
CaM-F142L Impairs Ca\(^{2+}\) Binding but Not RyR2 Inhibition

FIGURE 3. Effect of CaM-WT and mutants on single RyR2 channel properties. A–C, example of single RyR2 channel current traces without CaM (left traces) and after the addition of 1 μM CaM. D–F, RyR2 channel P\(_o\), MOT, and MCT after the addition of CaM mutants (Ctrl with no added CaM). Measurements were done at +40 mV with 1 mM free Ca\(^{2+}\) at the luminal face and 10 μM free Ca\(^{2+}\), 1 mM free Mg\(^{2+}\), and 1 mM ATP at the cytosolic face. The a indicates values significantly different from CaM-WT, and b indicates values significantly different from Ctrl (t test, p < 0.05). Error bars show S.E. from 6–8 channels for each CaM variant and 32 channels before or without CaM addition (Ctrl).

CaM and CaM binding to the RyR2 CaMBD (2, 29, 31). The CaM-F142L mutation clearly impairs Ca\(^{2+}\) binding to the CaM C-domain in the absence of a CaM binding target (2, 29, 31). Given the limited action of the CaM-F142L mutant on SOICR in HEK293 cells and its GoF action at the single RyR2 channel level, we assessed whether the CaM-F142L mutation differentially affects CaM Ca\(^{2+}\) affinity when the CaM is bound to the RyR2 CaMBD. The binding of Ca\(^{2+}\) to CaM in the presence of the CaMBD (i.e. the RyR2(R3581-L3611) peptide) was determined using a Ca\(^{2+}\) titration while monitoring the intrinsic protein fluorescence specific for each CaM domain (Phe for the N-domain and Tyr for the C-domain) (Fig. 4). Fitting the apparent dissociation constant (app\(K_d\)) for either CaM domain using a two-site Adair model revealed that the CaM-F142L mutation lowered the affinity of the C-domain for binding Ca\(^{2+}\) in the presence of CaMBD, thus altering the thermodynamics of CaM-Ca\(^{2+}\). This measurement compares the differences in the CaMBD interaction aside from those caused by differences in CaM Ca\(^{2+}\) binding affinity. The binding of apo- or CaCaM-WT to the CaMBD peptide represent two thermodynamically distinct reactions. The apoCaM-WT/CaMBD interaction is comparatively low affinity (μM \(K_d\)) and is entropy-driven (\(\Delta H^o > 0, -T\Delta S^o < 0\)). The CaCaM-WT/CaMBD interaction is high affinity (nM \(K_d\)) and is enthalpy-driven (\(\Delta H^o < 0, -T\Delta S^o > 0\)) (Figs. 5–7) (26).

The ITC measurements showed a fundamental difference in the thermodynamics of apoCaM-F142L binding to the CaMBD compared with the apoCaM-WT (Fig. 5, A–C). The binding reaction between apoCaM-F142L and the CaMBD peptide was exothermic (\(\Delta H^o < 0\)) in marked contrast to the endothermic (\(\Delta H^o > 0\)) interaction between apoCaM-WT and the CaMBD. Moreover, titration curve analysis showed that apoCaM-F142L binding affinity for the CaMBD was ~3-fold greater compared with that of apoCaM-WT (\(K_d\) 9 versus 28 μM) (Fig. 6A).
CaM-F142L Impairs Ca$^{2+}$ Binding but not RyR2 Inhibition

ApoCaM-F142L binding also displayed a small negative $\Delta H^o$ (−1.8 kJ/mol) compared with the larger, positive $\Delta H^o$ (11.8 kJ/mol) for apoCaM-WT binding (Fig. 6B). A comparison of the fitted $\Delta H^o$ values to the $-T\Delta S^o$ values (−38 and −27 kJ/mol for apoCaM-WT and -F142L) indicated that the binding of both apoCaM-WT and -F142L to the CaMBD peptide remained governed by entropy ($-T\Delta S^o$) relative to enthalpy ($\Delta H^o$) (Fig. 6C). The change in $\Delta H^o$ conferred by the CaM-F142L mutation translated into a significant 11% decrease ($-26$ kJ/mol) in $\Delta G^o$ for the apoCaM-F142L interaction with the CaMBD peptide (Fig. 6D). Generally, an enthalpy-driven reaction is indicative of specific molecular bonding, whereas an entropy-driven reaction indicates hydrophobic interactions and solvent effects (32). Thus, these ITC results indicated that the CaM-F142L mutation transformed the apoCaM interaction from mainly entropy-driven to one more dominated by molecular bonds. Under saturating Ca$^{2+}$ conditions, the interaction between CaCaM-F142L and the CaMBD peptide was indistinguishable from that for the CaCaM-WT (Figs. 5, C, and D, and 6). Interestingly, the increase in affinity comparing Ca$^{2+}$-free to saturating Ca$^{2+}$ conditions was still 3 orders of magnitude ($K_{app} = 8$ μM versus 14 nm) for CaM-F142L, attributable to an increased $\Delta H^o$ contribution under the CaCaM condition. Thus, the thermodynamic difference between apo and CaCaM binding to the CaMBD peptide remained similar for CaCaM-WT and -F142L.

The interactions of CaM-D96V and -N98S with the RyR2 CaMBD peptide were also investigated using ITC, and for both Ca$^{2+}$ conditions neither of those for the CaM-WT. However, detailed titration curve analysis indicated a slightly decreased affinity of CaM-D96V for CaMBD binding with and without Ca$^{2+}$ present (Figs. 5, C and F, and 6A). Small changes to $\Delta H^o$ were also detected for apoCaM-D96V and -N98S and for CaCaM-D96V and -N98S (Fig. 6B). Interestingly, the minute effects observed for CaM-D96V and -N98S were all significantly distinct from those observed for CaM-F142L under both Ca$^{2+}$ conditions. Thus, CaM-F142L generally showed CaMBD binding properties different from not only the CaM-WT but also from the other arrhythmogenic CaM mutations, D96V and N98S.

Motivated by the results from the ITC experiment, we used 2D NMR (15N-HSQC) to measure the effect of Ca$^{2+}$ on the chemical shifts from a CaMBD peptide with $^{15}$N-labeled Val-3586 and Phe-3603 in a complex with CaM-WT, -N98S, or -F142L. The chemical shifts of these labeled residues depend on their immediate structural surroundings (i.e. the binding of the CaM C- and N-domain, respectively). The peaks corresponding to Val-3586 and Phe-3603 were easily discernible under apoCaM conditions (Fig. 7A). Unfortunately, their chemical shifts overlapped under saturating Ca$^{2+}$ conditions (Fig. 7B). Nonetheless, a clear difference under apoCaM conditions was observed for CaM-CaMBD complexes containing CaM-F142L compared with CaM-WT or -N98S. ApoCaM-F142L displayed a higher chemical shift for the Val-3586 HN but showed no differences for the Phe-3603 H\textsubscript{\alpha} or N. The latter observation may reflect that the N-domains of apoCaM-F142L and -WT do not bind to the CaMBD peptide. Under saturating Ca$^{2+}$ conditions, no differences in the spectra were observed, albeit the addition of Ca$^{2+}$ clearly affected the structural surroundings of the labeled residues (i.e. chemical shifts for both Val-3586 and Phe-3603 changed markedly). Opposite CaM-F142L, the spectra recorded using CaM-N98S were identical to those for CaM-WT, with and without Ca$^{2+}$ (Fig. 7, A and B). Taken together, these results support the notion that the apoCaM-F142L C-domain binds to the RyR2 CaMBD peptide close to the Val-3586 residue (next to Trp-3587) in a unique conformation structurally distinct from that of the apoCaM-WT and -N98S.

Discussion

CaM is a constitutive Ca$^{2+}$ sensor of the RyR2 macro-molecular complex, where it inhibits RyR2 Ca$^{2+}$ release in a [Ca$^{2+}$]$_{cyt}$ dependent, allosteric manner (3, 12, 34). This inhibition is critical for maintaining a low RyR2 activity at diastole (i.e. at low [Ca$^{2+}$]$_{cyt}$) and also for a sufficient termination of the Ca$^{2+}$ release during cardiac excitation (i.e. as [Ca$^{2+}$]$_{cyt}$ increases) (8, 23, 27–29, 33, 35, 36). The details of how the two
CaM-F142L Impairs Ca\textsuperscript{2+} Binding but Not RyR2 Inhibition

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure5}
\caption{ITC example data for the titration of the RyR2(R3581-P3607) peptide with CaM. Example ITC thermograms for apoCaM-WT and -F142L (A and B) and for CaCaM conditions (D and E). C and F, averaged integrated change in enthalpy per injection (\(\Delta H^o\)) comparing CaM-WT, -D96V, -N98S, and -F142L under apo (C) or CaCaM conditions (F). Without Ca\textsuperscript{2+} present, the binding of apoCaM-WT to the peptide is an endothermic reaction (positive \(\Delta H^o\)), whereas for the apoCaM-F142L the interaction is exothermic (A and B). With saturating Ca\textsuperscript{2+} present, both CaCaM-WT and -F142L display exothermic binding reactions (D and E). Thermograms for CaM-D96V and -N98S were not visibly different from those for the CaM-WT and therefore are not shown. DP, change in ITC instrument heat effect.}
\end{figure}

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure6}
\caption{Fitted thermodynamic parameters for the binding of CaM variants to the RyR2(R3581-P3607) peptide as calculated from ITC. Panels in the upper row summarize values for the apoCaM condition, and those in the lower row summarize values for CaCaM. A, the affinity of CaM for binding to the peptide expressed as the dissociation constant \(K_D\). B and C, enthalpy (\(\Delta H^o\)) and entropy contribution (\(\Delta S^o\)), respectively, for the binding interaction between CaM and the peptide. D, the change in Gibb’s free energy (\(\Delta G^o\)) as conferred by the CaM mutations. Error bars show S.D. The a and b indicate values significantly different from those for apoCaM-WT or CaM-F142L, respectively (one-way ANOVA, \(p < 0.05\)).}
\end{figure}

Ca\textsuperscript{2+}-sensing domains of CaM interact with Ca\textsuperscript{2+} and RyR2 to facilitate this complex inhibition are not well understood (3, 13, 26, 34). However, the interactions between the RyR2 CaMBD, the CaM C-domain and Ca\textsuperscript{2+} are critical for the physiological regulation of RyR2 Ca\textsuperscript{2+} release (8, 23, 24, 27–29, 36). Binding of the apoCaM C-domain to the CaMBD inhibits RyR2 Ca\textsuperscript{2+} release, whereas binding of Ca\textsuperscript{2+} to the CaM C-domain further increases this CaM-dependent inhibition (8, 23, 27–29, 35, 36). Based on the biophysical results for the tripartite interaction (CaM, RyR2 CaMBD, and Ca\textsuperscript{2+}) and the effects of arrhythmogenic CaM mutations, we proposed previously that the CaM C-domain at diastolic \([\text{Ca}^{2+}]_{cyt}\) binds to RyR2 CaMBD in a near Ca\textsuperscript{2+}-saturated state (1, 8, 27). In this scheme, the reduced affinity for Ca\textsuperscript{2+} binding of the arrhythmogenic CaM C-domain mutations (D96V, N98S, and D130G) causes the CaM C-domain to be less Ca\textsuperscript{2+}-saturated and thereby reduces the CaM-dependent inhibition of RyR2 (8).

The LQTS-causing CaM-F142L mutation clearly reduces the C-domain Ca\textsuperscript{2+} binding affinity (\(appK_D = 15\) \(\mu M\)), compared with CaM-WT (\(appK_D = 2.5\) \(\mu M\)). This is similar to what was observed for the CaM-N98S and -D96V mutants (\(appK_D = 10\) and 31 \(\mu M\)), albeit less than for CaM-D130G (\(appK_D = 84\) \(\mu M\)) (2, 17). Here, we found that this reduced affinity for the CaM-F142L C-domain Ca\textsuperscript{2+} binding was retained in the presence of the RyR2 CaMBD peptide, even to the extent that CaM-F142L displayed a lower affinity than CaM-D96V (\(appK_D = 0.32\) versus 0.14 \(\mu M\)) (Fig. 4).

Thus, we expected that in HEK293 cells where \([\text{Ca}^{2+}]_{cyt}\) oscillates between \(-0.1\) and 2 \(\mu M\), CaM-F142L would abnormally
Together, these results indicate that the F142L mutation causes cardiac SR vesicles to the same extent as the CaM-WT. Taken amino acid sequence of the RyR2(R3581-L3611) peptide with 15N-labeled residues.

\[ \text{Ca}^{2+} \text{binding} \]

15N-hydrogen HSQC NMR spectra of the RyR2(R3581-L3611) peptide with 15N-labeled residues highlighted in Fig. 1. Spectra were color-coded according to the CaM variant in the protein-peptide complex. C, amino acid sequence of the RyR2(R3581-L3611) peptide with 15N-labeled residues highlighted in bold and underlined. The CaM C-domain binds around Trp-3587 and the N-domain around Phe-3603.

regulate RyR2 function (compared with CaM-WT) to a similar extent as CaM-N98S and -D96V (Fig. 2) (37, 38). Curiously, the action of CaM-F142L on RyR2 function in the HEK293 SOICR assay was relatively benign and distinct from the actions of the CaM-N54I, -D96V, -N98S, and -D130G mutants (8). Moreover, these other CaM mutants were expressed using low expressing plasmids, resulting in a CaM ratio of \( \approx 1.4 \) relative to endogenous CaM (8). The expression plasmid used in this study, and also in Tian et al. (27), results in a CaM ratio of \( \approx 4 \) relative to endogenous CaM as judged from Western blotting analysis (Fig. 8). This further supports that the decrease in RyR2 inhibition caused by CaM-F142L was strikingly less than the decreases caused by CaM-N54I, -D96V, -N98S, and -D130G. Lastly, we observed no difference between CaM-F142L and -WT when the low expressing plasmid was used (data not shown). Consistent with these results, Hwang et al. (7) report similar spontaneous Ca\(^{2+}\) wave frequencies in permeabilized cardiomyocytes ([Ca\(^{2+}\)]\text{free}) at 0.12 \( \mu \text{M} \) with CaM-WT or CaM-F142L present. Also, Vassilakopoulou et al. (10) report that CaM-F142L inhibits binding of \([3^H]\)ryanodine to porcine cardiac SR vesicles to the same extent as the CaM-WT. Taken together, these results indicate that the F142L mutation causes little or no loss of CaM-dependent RyR2 inhibition, despite a pronounced LoF in terms of CaM C-domain Ca\(^{2+}\) binding. Even more strikingly though, we showed that at 10 \( \mu \text{M} \) cytosolic [Ca\(^{2+}\)]\text{free}, CaM-F142L is a more potent inhibitor of single RyR2 channels than CaM-WT. Specifically, CaM-F142L promoted a much faster RyR2 closing (Fig. 3). In other words, CaM-F142L displayed a GoF action in that it increased the CaM-dependent RyR2 inhibition.

How can the F142L mutation confer both a LoF in terms of Ca\(^{2+}\) binding with seemingly little consequence to the RyR2 inhibitory action in cells and a robust RyR2 inhibitory action at the single channel level? Our ITC experiments hint at a potential explanation. ApoCaM-F142L showed increased affinity for binding the RyR2 CaMBD peptide and bound in a manner thermodynamically in between that of the apoCaM-WT and CaM-WT interactions (Figs. 5 and 6). The NMR HSQC spectra also support this view demonstrating that the apoCaM-F142L C-domain bound around Val-3586 in the CaMBD in a conformation that was structurally distinct from that of the apoCaM-WT. Based on our functional, biophysical, and structural results, we propose that the F142L mutation has two opposing actions on RyR2 regulation.

First, the F142L mutation enhances the CaM C-domain interactions with the RyR2 CaMBD, thus increasing RyR2 inhibition (GoF). Second, the CaM-F142L C-domain has impaired Ca\(^{2+}\) binding (LoF), thus decreasing RyR2 inhibition. Under the comparatively low [Ca\(^{2+}\)]\text{cyt} conditions in HEK293 cells or the permeabilized cardiomyocytes (7), the effect of reduced CaM-F142L C-domain Ca\(^{2+}\) binding would be partially offset by the enhanced CaM binding to the RyR2 CaMBD, explaining why little aberrant RyR2 regulation was observed. However, increasing Ca\(^{2+}\) saturates the CaM-F142L C-domain (appK\(_D\) = 0.32 \( \mu \text{M} \)), in effect ablating any LoF action from the reduced C-domain Ca\(^{2+}\) affinity. Accordingly, at high Ca\(^{2+}\) concentrations only the GoF action would remain and may explain why CaM-F142L was a more potent inhibitor than the CaM-WT in our single RyR2 channel studies. The molecular basis for this GoF effect was not clear from these experiments, as no differences between CaCaM-WT and CaCaM-F142L binding to the RyR2 CaMBD peptide were detected. This implies perhaps that interactions between CaM and RyR2 not recapitulated in our biophysical experiments, e.g. RyR2 regions outside the CaMBD studied here, are responsible for the GoF action. Structurally delineating this GoF action may provide a molecular guide for how to manipulate the CaM-dependent RyR2 inhibition. Also, increasing this inhibition reduces SR Ca\(^{2+}\) release and/or leak and thus represents a therapeutic approach for treating heart failure and arrhythmia (28, 31, 39 – 41).
Aside from the novel insights into the effects of CaM-F142L on RyR2 regulation, our single RyR2 channel experiments support our previous finding that both CPVT- and LQTS-causing CaM mutations (N98S, D96V, and D130G) result in aberrant RyR2 regulation (8). Using different experimental conditions (sheep cardiomyocytes, 0.1 mm luminal [Ca$^{2+}$]$_{i,free}$ 2 mm ATP cytosolic, and no Mg$^{2+}$), Hwang et al. (7) report that CaM-N54I and -N98S increased RyR2 $P_o$ at 0.1 and 1 $\mu$M cytosolic [Ca$^{2+}$]$_{i,free}$ whereas CaM-D96V did not. The apparent CaM-D96V discrepancy between our study and the Hwang et al. study (7) may be explained by differences in the experimental conditions. Our study shows that CaM mutations N54I, D96V, N98S, D130G, and F142L alter the RyR2 CaM regulation via distinct molecular mechanisms. The CaM-D96V, -N98S, and -D130G mutations diminish C-domain Ca$^{2+}$ binding and thereby the inhibitory interaction of CaM with the RyR2 CaMBD. The N-domain CaM-N54I mutation likely affects CaM-RyR2 interactions that are outside the canonical CaMBD and/or increases Ca$^{2+}$ binding kinetics (17). The CaM-F142L mutation diminishes C-domain Ca$^{2+}$ binding but also enhances CaM interaction with the RyR2 CaMBD and possibly other regions (7, 8, 10, 17). Because LQTS-causing CaM-D96V, -N98S, and -D130G mutations diminish CaM-dependent RyR2 inhibition, increased RyR2 Ca$^{2+}$ release may contribute to the LQTS phenotypes in individuals with these CaM mutations. Generally, it is thought that spontaneous diastolic RyR2 Ca$^{2+}$ release causes CPVT, and augmented Ca$^{2+}$ influx through Ca$_{1.2}$ channels causes LQTS (see Refs. 42 and 43 for details). Studies using recombinant Ca$_{1.2}$ and patch clamping show that Ca$^{2+}$-dependent inactivation of Ca$_{1.2}$ is reduced when CaM-D96V, -N98S, -D130G and -F142L are present (compared with CaM-WT) (6, 9).

Thus, some mechanistic overlap between CPVT and LQTS caused by CaM mutations likely exist, and how arrhythmogenic CaM mutations manifest probably depends on their relative effects on RyR2, Ca$_{1.2}$, and other CaM-regulated targets. The best example of this is CaM-N98S, which affects both RyR2-mediated Ca$^{2+}$ release and Ca$_{1.2}$ Ca$^{2+}$-dependent inactivation, likely contributing to both CPVT and LQTS. Another scenario is represented by the strictly CPVT-causing CaM-N54I mutation, which does not affect Ca$_{1.2}$ Ca$^{2+}$-dependent inactivation (1, 4, 6, 44). In addition, some CaM C-domain mutations (N98S, D132E, and Q136P) are reported to cause a LQTS phenotype with some features of CPVT overlapping (4, 44). β-Blockers are the common drug treatment for both CPVT and LQTS (42, 43). Given the differential influence of CaM mutations on Ca$_{1.2}$ and RyR2, drugs that preferentially alter RyR2 or Ca$_{1.2}$ function might provide better treatments for CaM-mediated arrhythmias (42, 43, 45). Novel drugs affecting RyR2 and Ca$_{1.2}$ are being sought (45–47), and as antiarrhythmic therapies advance, defining their differential action on Ca$_{1.2}$ and RyR2 function will almost certainly become increasingly relevant.

**Experimental Procedures**

**Plasmid Constructs**—Plasmid constructs for the recombinant expression and purification of CaM (pMAL, New England Biolabs) or for overexpression of CaM in HEK293 cells (pcDNA3.1, Invitrogen) were prepared as described previously (8). Sanger sequencing verified the CaM-encoding inserts in all plasmids.

**Endoplasmic Reticulum Luminal Ca$^{2+}$ Imaging of HEK293 Cells Expressing RyR2—** Stable expression of murine RyR2, or a RyR2 variant with the CaMBD deleted (murine ΔK3583-F3603), in HEK293 cells co-transfected with plasmids encoding CaM and the D1ER Ca$^{2+}$ probe was done as described previously (27). Briefly, D1ER FRET signals reflecting ER luminal [Ca$^{2+}$]$_{i,free}$ in individual cells were monitored by using an epifluorescent microscope (27, 48). Each FRET signal trace was used to measure the Ca$^{2+}$ release properties of the RyR2 channels relative to the ER Ca$^{2+}$ store capacity: the activation and termination thresholds and their difference taken as the fractional Ca$^{2+}$ release. The ER Ca$^{2+}$ store capacities were calculated from the difference between maximum and minimum FRET signal ($F_{max} - F_{min}$) (Fig. 2). The measured RyR2 Ca$^{2+}$ release properties were compared using one-way ANOVA with Tukey’s multiple comparisons test for all possible combinations, with adjusted $p < 0.05$ taken as significant. The experiments included a control without plasmid expression of CaM.

**Estimation of CaM-WT and RyR2 Expression Levels in HEK293 Cells—** HEK293 cells were cultured as described above with CaM-WT overexpression from a low (8) or high expressing plasmid (this study and Ref. 27) and without overexpression (Ctrl). Overexpression plasmids differed in their Kozak sequences upstream of the CALM1 cDNA inserts. 40 µg of total protein from cell lysates (protein assay, Bio-Rad) was subjected to SDS-PAGE (1 h at 20 A) in a gradient gel (Bio-Rad, Mini-Protein TGX 4–20%) alongside a molecular weight marker (Bio-Rad, catalog No. 161-0309), and the electrophoretic separated proteins were blotted (0.5 h at 100 V, –0.33 A) to a nitrocellulose membrane in Tris-glycine buffer (Bio-Rad) with 10‰ SDS. The membrane was transiently stained with Ponceau S and cut into three regions: RyR2 (~500 kDa), β-actin (~42 kDa), and CaM (~16 kDa). The membrane pieces were blocked in PBS with 1% casein (Bio-Rad), washed in PBS, and then incubated overnight with different primary antibodies (Ab) against CaM (05-173, EMD Milipore), β-actin (A5316, Sigma), or RyR2 (MA3-925, Pierce) in PBS with 1% Ab, 20% fetal bovine serum (Sigma), and 17 mM NaN$_3$. After another wash, the pieces were incubated for 0.5 h with a secondary Ab (in-house anti-mouse IgG conjugated to horseradish peroxidase) and then washed again. The amount of bound secondary Ab was detected using luminal reagent (detection reagent 1–2, Thermo Scientific) with the resulting chemiluminescence imaged (ImageQuant LAS 4000, GE Healthcare Life Sciences). As a measure of protein expression levels, the protein band area intensities were quantified in ImageJ, and the expression levels of RyR2 and CaM in the individual samples were normalized to that of β-actin (49) (Fig. 8, normalized area). Western blotting analysis was done in at least duplicate.

**Bilayer Recordings of Single RyR2 Channels—** Native SR microsomes isolated from rat ventricular muscle were incorporated into bilayers using a modification of the method described by Chamberlain et al. (47, 50, 51). Briefly, planar lipid bilayers (50 mg/ml in a 5:4:1 mixture of bovine brain phosphatidylethanolamine, -serine, and -choline in n-decane).
were formed across a 100-μm-diameter hole in a Teflon partition separating two compartments with cytosolic (114 mM Tris-HEPES, 5 mM ATP, 1 mM free Mg$^{2+}$, 1 mM EGTA, and 10 μM free Ca$^{2+}$ at pH 7.4) and luminal (cytosolic solution plus 200 mM Cs-HEPES and 1 mM free Ca$^{2+}$) recording solutions. Single RyR2 activity was measured before and 20 min after the addition of CaM variants (1 μM) to the cytosolic solution. Recordings were made at room temperature (20–22 °C) with currents sampled at 50 μs/point and filtered at 0.75 kHz (4-pole Bessel). Analysis was done using pCLAMP9 software (Molecular Devices, Sunnyvale, CA). Recapitulating the cytosolic and intra-SR cellular milieu in vitro during planar lipid bilayer studies is impossible. Consequently, experimental compromises were necessary, and here the solutions approximated those in cardiomyocytes during systole. Low cytosolic Ca$^{2+}$ (0.1–1 μM) reduces RyR2 activity to a level unsuitable for reliable measurements. Some researchers have overcome this issue by omitting Mg$^{2+}$, but this causes a very non-physiological RyR2 Ca$^{2+}$ dependence, as in cells Mg$^{2+}$ normally competes with Ca$^{2+}$ for occupancy of RyR2 cytosolic Ca$^{2+}$ activation and inactivation sites. Differences in single channel parameters ($P_o$, MOT, and MCT) extracted from time traces were compared using two-tailed t tests against the values following the addition of CaM-WT with $p < 0.05$ considered significant. Also, comparisons with control (no addition of CaM) were done with the same $p$ value criteria.

**Protein Expression and Purification**—CaM was expressed from the pMAL vectors and purified as described previously (8). The identity, purity, and integrity of each protein preparation was confirmed by SDS-PAGE and MALDI-TOF mass spectrometry of trypsin-digested proteins.

**CaM Ca$^{2+}$ Titrations in the Presence of the RyR2(R3581-L3611) Peptide**—A peptide corresponding to the RyR2 CaMBD (human RyR2 3581RSKKAVWHKLSSKQRKRAVVACFRMAP3607) was purchased from GenScript (Piscataway, NJ) at >95% purity. Titration of the RyR2(R3581-L3607) peptide with CaM was investigated under both Ca$^{2+}$-free (apo) and Ca$^{2+}$-saturating conditions and followed the use of ITC. Purified CaM variants were dialyzed (10 K Slide-a-lyzer™, Thermo Scientific) against the cytosolic solution plus 200 mM D$_2$O, 40 μM TCEP, and 15N-labeled at Val-3586 and Phe-3603 (15N-RyR2(R3581-L3611)) was purchased from GenScript (Piscataway, NJ) at >95% purity. Titration experiments were done as described previously (8). Briefly; pH- and Ca$^{2+}$-buffered solutions (50 mM HEPES, 100 mM KCl, 0.5 mM EGTA, and 2 mM NTA at pH 7.2 (25 °C)) with or without 7 mM CaCl$_2$ were mixed to obtain different [Ca$^{2+}$]$_{free}$ levels (52). CaM (15 μM), RyR2(R3581-L3611) peptide (16.5 μM), 16.5 μM TCEP, and Fura-2 (Invitrogen) Ca$^{2+}$ probe (0.8 μM) were added to double distilled water for dilution of 1.5× concentrated buffers. A 15% error for the [Ca$^{2+}$]$_{free}$ was included in data fitting procedures based on measuring [Ca$^{2+}$]$_{free}$ using Fura-2 and Ca$^{2+}$ binding to CaM-WT. The intrinsic protein fluorescence from each CaM domain was monitored during CaM/RyR2 CaMBD complex Ca$^{2+}$ titrations. The titration curves were fitted to a two-site Adair function as described previously (8, 19, 53, 54). Briefly, fluorescence intensities (FI) from the N- and C-domains of CaM were measured as partial Phe and Tyr emission spectra, and the fractional saturations (Y) for each domain were fitted to the raw FI according to Equation 1,

$$FI = Y \times a + b \quad \text{(Eq. 1)}$$

where b and a are the initial FI and the span in FI, respectively. Y is the fractional saturation of the monitored CaM domain binding two Ca$^{2+}$ as described by the two-site Adair model,

$$Y = \frac{K_1 \times [X] + 2 \times K_2 \times [X]^2}{2 \times (1 + [X]) + K_2 \times [X]^2} \quad \text{(Eq. 2)}$$

where $K_1$ is the sum of the microscopic equilibrium constants, and $K_2$ is the equilibrium constant for the domain binding to two Ca$^{2+}$. The apparent dissociation constant (app$K_d$) for either domain was then calculated as the reciprocal square root of $K_2$. The fitted $K_2$ values were compared using one-way ANOVA with Dunnett’s multiple comparison test against the value for CaM-WT/RyR2(R3581-L3611) titrations.

**Isothermal Titration Calorimetry of RyR2(R3581-P3607) Peptide with CaM**—A peptide corresponding to the CaMBD (human RyR2 3581RSKKAVWHKLSSKQRKRAVVACFRMAP3607) was purchased from GenScript (Piscataway, NJ) at >95% purity. Titration of the RyR2(R3581-L3607) peptide with CaM was investigated under both Ca$^{2+}$-free (apo) and Ca$^{2+}$-saturating conditions and followed the use of ITC. Purified CaM variants were dialyzed (10 K Slide-a-lyzer™, Thermo Scientific) against the cytosolic solution plus 200 mM D$_2$O, 40 μM TCEP, and 15N-labeled at Val-3586 and Phe-3603 (15N-RyR2(R3581-L3611)) was purchased from GenScript (Piscataway, NJ) at >95% purity. Titration experiments were done as described previously (8). Briefly; pH- and Ca$^{2+}$-buffered solutions (50 mM HEPES, 100 mM KCl, 0.5 mM EGTA, and 2 mM NTA at pH 7.2 (25 °C)) with or without 7 mM CaCl$_2$ were mixed to obtain different [Ca$^{2+}$]$_{free}$ levels (52). CaM (15 μM), RyR2(R3581-L3611) peptide (16.5 μM), 16.5 μM TCEP, and Fura-2 (Invitrogen) Ca$^{2+}$ probe (0.8 μM) were added to double distilled water for dilution of 1.5× concentrated buffers. A 15% error for the [Ca$^{2+}$]$_{free}$ was included in data fitting procedures based on measuring [Ca$^{2+}$]$_{free}$ using Fura-2 and Ca$^{2+}$ binding to CaM-WT. The intrinsic protein fluorescence from each CaM domain was monitored during CaM/RyR2 CaMBD complex Ca$^{2+}$ titrations. The titration curves were fitted to a two-site Adair function as described previously (8, 19, 53, 54). Briefly, fluorescence intensities (FI) from the N- and C-domains of CaM were measured as partial Phe and Tyr emission spectra, and the fractional saturations (Y) for each domain were fitted to the raw FI according to Equation 1,
and CALM3-encoded calmodulin (CaM) variants in long QT syndrome (LQTS) and functional characterization of a novel LQTS-associated CaM missense variant, E141G. Circ. Cardiovasc. Genet. 9, 136–146

12. Fearnley, C. J., Roderick, H. L., and Bootman, M. D. (2011) Calcium signaling in cardiac myocytes. Cold Spring Harb. Perspect. Biol. 3, a004242

13. Van Petegem, F. (2015) Rydno receptors: allosteric ion channel giants. J. Mol. Biol. 427, 31–53

14. Berridge, M. J. (2014) Cell signalling biology: Module 7-cellular processes. Biochem. J. 410.1042/csb0010007

15. Linse, S., Helmersson, A., and Forsén, S. (1991) Calcium binding to calmodulin and its globular domains. J. Biol. Chem. 266, 8050–8054

16. Zhang, M., Abrams, C., Wang, L., Gizi, A., He, L., Lin, R., Chen, Y., Loll, P. J., Pascal, J. M., and Zhang, J. F. (2012) Structural basis for calmodulin as a dynamic calcium sensor. Structure 20, 911–923

17. Søndergaard, M. T., Sorensen, A. B., Skov, L. L., Kjaer-Sorensen, K., Bauer, M. C., Nyegaard, M., Linse, S., Oxvig, C., and Overgaard, M. T. (2015) Calmodulin mutations causing catecholaminergic polymorphic ventricular tachycardia confer opposing functional and biophysical molecular changes. FEBS J. 282, 803–816

18. Pedigo, S., and Shea, M. A. (1995) Discontinuous equilibrium titrations of cooperative calcium binding to calmodulin monitored by 1-D IH magnetic resonance spectroscopy. Biochemistry 34, 10676–10689

19. Vancscoy, W. S., Sorensen, B. R., Rusinova, E., Laws, W. R., Ross, J. B., and Shea, M. A. (2002) Calcium binding to calmodulin mutants monitored by domain-specific intrinsic phenylalanine and tyrosine fluorescence. Bio- phys. J. 83, 2767–2780

20. Jiang, J., Zhou, Y., Zou, J., Chen, Y., Patel, P., Yang, J. J., and Balog, E. M. (2010) Site-specific modification of calmodulin Ca2+ (s) affinity tunes the skeletal muscle rymodulin receptor activation profile. Biochem. J. 432, 89–99

21. Saimi, Y., and Kung, C. (2002) Calmodulin as an ion channel subunit. Annu. Rev. Physiol. 64, 289–311

22. Ben Johny, M., Yang, P. S., Bassazzi, H., and Yue, D. T. (2013) Dynamic switching of calmodulin interactions underlies Ca2+ (s) regulation of CaV1.3 channels. Nat. Commun. 4, 1717–1717

23. Yamaguchi, N., Xu, L., Pasek, D. A., Evans, K. E., and Meissner, G. (2003) Molecular basis of calmodulin binding to cardiac muscle Ca2+ (s) release channel (ryanodine receptor). J. Biol. Chem. 278, 23480–23486

24. Fruen, B. R., Black, D. J., Bloomquist, R. A., Barty, J. M., Johnson, J. D., Louis, C. F., and Balog, E. M. (2003) Regulation of the RYR1 and RYR2 Ca2+ release channel isoforms by Ca2+ -insensitive mutants of calmodulin. Biochemistry 42, 2740–2747

25. Maxinuciu, A. A., Putkey, J. A., Shamooy, Y., and Mackenzie, K. R. (2006) Complex of calmodulin with a vondione receptor target reveals a novel, flexible binding mode. Structure 14, 1547–1556

26. Lau, K., Chan, M. M., and Van Petegem, F. (2014) Lobe-specific calmodulin binding to different rymodulin receptor isoforms. Biochemistry 53, 992–946

27. Tian, X., Tzeng, H.-Y., Liu, Y., Wang, R., and Chen, S. R. (2013) Calmodulin modulates the termination threshold for cardiac rymodulin receptor-mediated Ca2+ release. Biochem. J. 455, 367–375

28. Yang, Y., Guo, T., Oda, T., Chakraborty, A., Chen, L., Uchinoumi, H., Knowlton, A. A., Fruen, B. R., Cornea, R. L., Meissner, G., and Bers, D. M. (2014) Cardiac myocyte Z-line calmodulin is mainly RyR2-bound, and reduction is arrhythmogenic and occurs in heart failure. Circ. Res. 114, 295–306

29. Arnáiz-Cot, J. J., Damian, B. J., Zhang, X. H., Cleemann, L., Yamaguhi, N., Meissner, G., and Morad, M. (2013) Cardiac calcium signalling pathways associated with defective calmodulin regulation of type 2 rymodulin receptor. J. Physiol. (Lond.) 591, 4287–4299

30. Jones, P. J., Jiang, D., Bolstad, J., Hunt, D. J., Zhang, L., Damaarex, N., and Chen, S. R. (2008) Endoplasmic reticulum Ca2+ measurements reveal that the cardiac rymodulin receptor mutations linked to cardiac arrhythmia and sudden death altered the threshold for store-overload-induced Ca2+ release. Biochem. J. 412, 171–178

31. Ono, M., Yano, M., Hino, A., Suotomi, T., Xu, X., Susa, T., Uchinoumi, H., Tateishi, H., Oda, T., Okuda, S., Doi, M., Kobayashi, S., Yamamoto, T., Koseki, N., Kyushki, H., et al. (2010) Dissociation of calmodulin from...
cardiac ryanodine receptor causes aberrant Ca(2+) release in heart failure. *Cardiovasc. Res.* 87, 609–617

32. Holdgate, G. A. (2001) Making cool drugs hot: isothermal titration calorimetry as a tool to study binding energetics. *BioTechniques* 31, 164–184

33. Yamaguchi, N., Chakraborty, A., Huang, T. Q., Xu, L., Gomez, A. C., Pasek, D. A., and Meissner, G. (2013) Cardiac hypertrophy associated with impaired regulation of cardiac ryanodine receptor by calmodulin and S100A1. *Am. J. Physiol. Heart Circ. Physiol.* 305, H86–H94

34. Walweel, K., Oo, Y. W., and Laver, D. R. (2016) The emerging role of calmodulin regulation of RyR2 in controlling heart rhythm, the progression of heart failure and the antiarrhythmic action of dantrolene. *Clin. Exp. Pharmacol. Physiol.* 10.1111/1440–1681.12669

35. Xu, L., and Meissner, G. (2004) Mechanism of calmodulin inhibition of cardiac sarcoplasmic reticulum Ca2+ release channel (ryanodine receptor). *Biophys. J.* 86, 797–804

36. Yamaguchi, N., Takahashi, N., Xu, L., Smithies, O., and Meissner, G. (2007) Early cardiac hypertrophy in mice with impaired calmodulin regulation of cardiac muscle Ca release channel. *J. Clin. Invest.* 117, 1344–1353

37. Breitwieser, G. E., and Gama, L. (2001) Calcium-sensing receptor activation induces intracellular calcium oscillations. *Am. J. Physiol. Cell Physiol.* 280, C1412–C1421

38. Jiang, D., Xiao, B., Yang, D., Wang, R., Choi, P., Zhang, L., Cheng, H., and Chen, S. R. (2004) RyR2 mutations linked to ventricular tachycardia and sudden death reduce the threshold for store-overload-induced Ca2+ release (SOICR). *Proc. Natl. Acad. Sci. U.S.A.* 101, 13062–13067

39. Oo, Y. W., Gomez-Hurtado, N., Walweel, K., van Helden, D. F, Imtiaz, M. S., Knollmann, B. C., and Laver, D. R. (2015) Essential role of calmodulin 2 mutation N98S is associated with unexplained cardiac arrest in infants due to low clinical penetrance electrical disorders. *PLoS ONE* 11, e0153851

40. Oda, T., Yang, Y., Uchinoumi, H., Thomas, D. D., Chen-Izu, Y., Kato, T., Yamamoto, T., Yano, M., Cornea, R. L., and Bers, D. M. (2015) Oxidation of ryanodine receptor (RyR) structure and calmodulin affinity. *J. Mol. Cell. Cardiol.* 85, 240–248

41. Uchinoumi, H., Yang, Y., Oda, T., Puglisi, J. L., Chen-Izu, Y., Cornea, R. L., Wehrens, X. H. T., and Bers, D. M. (2016) CaMKII and heart failure promote a pathological ryanodine receptor conformation that reduces calmodulin binding and enhances SR Ca2+ leak. *Biophys. J.* 110, 599a

42. Venetucci, L., Denegri, M., Napolitano, C., and Priori, S. G. (2012) Inherited calcium channelopathies in the pathophysiology of arrhythmias. *Nat. Rev. Cardiol.* 9, 561–575

43. Mizusawa, Y., Horie, M., and Wilde, A. A. (2014) Genetic and clinical advances in congenital long QT syndrome. *Circ. J.* 78, 2827–2833

44. Jiménez-Jáimez, J., Palomino Doza, I., Ortega, Á., Macías-Ruiz, R., Perin, F., Rodríguez-Vázquez del Rey, M. M., Ortiz-Genga, M., Monserrat, L., Barriales-Villa, R., Blanca, E., Álvarez, M., and Tordera, L. (2016) Calmodulin 2 mutation N98S is associated with unexplained cardiac arrest in infants due to low clinical penetrance electrical disorders. *PLoS ONE* 11, e0153851

45. Driessen, H. E., Bourgonje, V. J., van Veen, T. A., and Vos, M. A. (2014) New antiarrhythmic targets to control intracellular calcium handling. *Neth. Heart J.* 22, 198–213

46. Zhou, Q., Xiao, J., Jiang, D., Wang, R., Vembaiyan, K., Wang, A., Smith, C. D., Xie, C., Chen, W., Zhang, J., Tian, X., Jones, P. P., Zhong, X., Guo, A., Chen, H., et al. (2011) Carvedilol and its new analogs suppress arrhythmogenic store overload-induced Ca2+ release. *17, Nat. Med.* 1003–1009

47. Tan, Z., Xiao, Z., Wei, J., Zhang, J., Zhou, Q., Smith, C. D., Nani, A., Wu, G., Song, L. S., Back, T. G., Fill, M., and Chen, S. R. (2016) Nebivolol suppresses cardiac ryanodine receptor-mediated spontaneous Ca2+ release and catecholaminergic polymorphic ventricular tachycardia. *Biochim. J.* 473, 4159–4172

48. Jiang, D., Wang, R., Xiao, B., Kong, H., Hunt, D. J., Choi, P., Zhang, L., and Chen, S. R. (2005) Enhanced store overload-induced Ca2+ release and channel sensitivity to luminal Ca2+ activation are common defects of RyR2 mutations linked to ventricular tachycardia and sudden death. *Circ. Res.* 97, 1173–1181

49. Schneider, C. A., Rasband, W. S., and Eliceiri, K. W. (2012) NIH Image to Image: 25 years of image analysis. *Nat. Methods* 9, 671–675

50. Chamberlain, B. K., Volpe, P., and Fleischer, S. (1984) Calcium-induced calcium release from purified cardiac sarcoplasmic reticulum vesicles: general characteristics. *J. Biol. Chem.* 259, 7540–7546

51. Qin, J., Valle, G., Nani, A., Chen, H., Ramos-Franco, J., Nori, A., Volpe, P., and Fill, M. (2009) Ryanodine receptor luminal Ca2+ regulation: swapping calsequerin and channel isoforms. *Biophys. J.* 97, 1961–1970

52. Dweck, D., Reyes-Alfonso, A., Jr., and Potter, J. D. (2005) Expanding the range of free calcium regulation in biological solutions. *Anat. Biochem.* 347, 303–315

53. Aday, G. (1925) The hemoglobin system: VI. The oxygen dissociation curve of hemoglobin. *J. Biol. Chem.* 63, 529–545

54. Shea, M. A., Verhoeven, A. S., and Pedigo, S. (1996) Calcium-induced calcium release (SOICR). *Am. J. Physiol. Cell Physiol.* 271, C1412–C1421

55. Schneider, C. A., Rasband, W. S., and Eliceiri, K. W. (2012) NIH Image to Image: 25 years of image analysis. *Nat. Methods* 9, 671–675

56. Chamberlain, B. K., Volpe, P., and Fleischer, S. (1984) Calcium-induced calcium release from purified cardiac sarcoplasmic reticulum vesicles: general characteristics. *J. Biol. Chem.* 259, 7540–7546

57. Qin, J., Val, G., Nani, A., Chen, H., Ramos-Franco, J., Nori, A., Volpe, P., and Fill, M. (2009) Ryanodine receptor luminal Ca2+ regulation: swapping calsequerin and channel isoforms. *Biophys. J.* 97, 1961–1970

58. Dweck, D., Reyes-Alfonso, A., Jr., and Potter, J. D. (2005) Expanding the range of free calcium regulation in biological solutions. *Anat. Biochem.* 347, 303–315

59. Aday, G. (1925) The hemoglobin system: VI. The oxygen dissociation curve of hemoglobin. *J. Biol. Chem.* 63, 529–545

60. Shea, M. A., Verhoeven, A. S., and Pedigo, S. (1996) Calcium-induced calcium release (SOICR). *Am. J. Physiol. Cell Physiol.* 271, C1412–C1421